Clinical Trial Update: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of GDC-9545 alone or in combination with palbociclib and/or an LHRH agonist in locally advanced or metastatic estrogen receptor-positive breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GDC-9545 (giredestrant)
• IBRANCE (PALBOCICLIB)
• LHRH agonist (Gonadotropin-releasing hormone (GnRH) agonist)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING